- Home
- RSLS
as 05-09-2025 4:00pm EST
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus. Geographically, the company operates in the United States, Australia, Europe, and the Rest of world, and the majority of its revenue is generated from the United States.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | SAN CLEMENTE |
| Market Cap: | 4.5M | IPO Year: | 2007 |
| Target Price: | N/A | AVG Volume (30 days): | 17.0M |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -13.83 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.30 - $29.00 | Next Earning Date: | 05-19-2025 |
| Revenue: | $8,006,000 | Revenue Growth: | -7.74% |
| Revenue Growth (this year): | 52.8% | Revenue Growth (next year): | N/A |
Latest ReShape Lifesciences Inc. News
RSLS Breaking Stock News: Dive into RSLS Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
ReShape Lifesciences Announces 1-for-25 Reverse Stock Split
GlobeNewswire
8 days ago
ReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation Symposium
GlobeNewswire
12 days ago
ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System
GlobeNewswire
19 days ago
ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology
GlobeNewswire
a month ago
ReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market
GlobeNewswire
a month ago
ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update
GlobeNewswire
2 months ago
ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology
GlobeNewswire
2 months ago
ReShape Lifesciences® Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band® 2.0 FLEX
Compare RSLS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RSLS ReShape Lifesciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.